Comorbid conditions associated with Parkinson's disease: A longitudinal and comparative study with Alzheimer disease and control subjects

Santos‐García, Diego; Castro, Ester Suárez; Expósito, Inmaculada; Deus, Teresa de; Tuñas, C.; Aneiros, Ángel; Fernández, M.; Arias, Diana; Torres, María Luisa García

doi:10.1016/j.jns.2016.12.046

Cited by 36 publications

(24 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, comorbidity and polypharmacy are important aspects to consider in PD patients because both influence the decisions made in daily clinical practice. It was observed that, as in previous studies , the number of drugs and pills taken per day was higher in PD patients than controls, including antidepressant agents and analgesics. As a whole, all these data reflect the concept of PD as a complex disorder with many different symptoms and that exhaustive evaluation of the patient is the best way to try to comprehend what problems are causing disability and a poor QoL.…”

Section: Discussionsupporting

confidence: 82%

COPPADIS‐2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015): an ongoing global Parkinson's disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation

Santos‐García

Jesús

Aguilar

et al. 2019

Euro J of Neurology

Self Cite

View full text Add to dashboard Cite

Background and purpose In Parkinson's disease (PD), the course of the disorder is highly variable between patients. Well‐designed, prospective studies for identifying PD progression biomarkers are necessary. Our aim was to show the results of baseline evaluations of an ongoing global PD project, COPPADIS‐2015 (Cohort of Patients with PArkinson's DIsease in Spain, 2015). Methods This was an observational, descriptive, nationwide study (Spain). The recruitment period ended in October 2017. Baseline evaluation included more than 15 validated scales and complementary studies in a subgroup of participants. Results In total, 1174 subjects from 35 centres were considered valid for baseline analysis: 694 patients (62.6 ± 8.9 years old, 60.3% males), 273 caregivers (58.5 ± 11.9 years old, 31.8% males) and 207 controls (61 ± 8.3 years old, 49.5% males). The mean disease duration was 5.5 ± 4.4 years. Hoehn and Yahr stage was 1 or 2 in 90.7% of the patients whilst 33.9% and 18.1% of them presented motor fluctuations and dyskinesias, respectively. The mean Non‐Motor Symptoms Scale total score was 45.4 ± 38.1, and 30.4% of the patients presented cognitive impairment, 16.1% major depression, 12.7% impulse control disorder, 7.2% compulsive behaviour, 57.2% pain and 13.2% falls. Compared to the control group, PD patients presented a significantly higher burden of non‐motor symptoms and a worse quality of life. More than 300 subjects conducted complementary studies (serum biomarkers, genetic and neuroimaging). Conclusions Parkinson's disease is a complex disorder and different non‐motor symptoms are frequently present and are more prevalent than in controls. In real clinical practice it is important to ask for them.

show abstract

Section: Discussionsupporting

confidence: 82%

COPPADIS‐2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015): an ongoing global Parkinson's disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation

Santos‐García

Jesús

Aguilar

et al. 2019

Euro J of Neurology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Mental health conditions were particularly prevalent (44%) which is consistent with the well-recognised neuropsychiatric manifestations of PD [ 16 ] and 31% (817/2640) had 5 or more conditions [ 10 ]. A smaller prospective cohort ( n = 147 PD patients) found a higher number of comorbidities in PD patients than in controls and noted an accumulation of comorbidity over 3 years [ 9 ]. Comorbidity predicted mortality after correcting for age, disease duration/stage, motor and non-motor symptoms (Hazard ratio 1.285 (95% confidence interval, 1.047– 1.577; p = 0.017)) [ 9 ].…”

Section: Comorbidity and Pdmentioning

confidence: 99%

“…A smaller prospective cohort ( n = 147 PD patients) found a higher number of comorbidities in PD patients than in controls and noted an accumulation of comorbidity over 3 years [ 9 ]. Comorbidity predicted mortality after correcting for age, disease duration/stage, motor and non-motor symptoms (Hazard ratio 1.285 (95% confidence interval, 1.047– 1.577; p = 0.017)) [ 9 ]. People with PD have more causes of death cited on death certificates than decedents of similar age with dementia and pneumonia being common contributors to death [ 17 ].…”

Section: Comorbidity and Pdmentioning

confidence: 99%

Multimorbidity and Frailty: Tackling Complexity in Parkinson’s Disease

Tenison

Henderson

2020

Journal of Parkinson’s Disease

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a condition that predominantly affects older people. It is imperative that clinical management considers the other significant illnesses that people with PD accumulate as they age in conjunction with their resilience to cope with physiological change. Multimorbidity and frailty act synergistically to heighten the risk of adverse outcomes for older people with PD. These states are associated with increased likelihood of hospitalization, polypharmacy, adverse drug effects including the anticholinergic burden of medications, drug-disease and drug-drug interactions. Management should be integrated, holistic and individualised to meticulously balance the risks of interventions considering the vulnerability of the individual to recover from disturbance to their environmental, physical and cognitive equilibrium.

show abstract

“…For example, a population-based study identified significant comorbid conditions including bone fractures, cancer, dementia, diabetes and stroke in PD patients (Leibson et al, 2006 ). A longitudinal study found hypertension and diabetes as the most frequent comorbidities in PD patients (Santos García et al, 2017 ). Recent studies have also shown that chronic diseases like anemia and cancer may be implicated in the pathogenesis of PD.…”

Section: Parkinson’s Disease: Beyond Motor Symptomsmentioning

confidence: 99%

Biological and Clinical Implications of Comorbidities in Parkinson’s Disease

Santiago

Bottero

Potashkin

2017

Front. Aging Neurosci.

View full text Add to dashboard Cite

A wide spectrum of comorbidities has been associated with Parkinson’s disease (PD), a progressive neurodegenerative disease that affects more than seven million people worldwide. Emerging evidence indicates that chronic diseases including diabetes, depression, anemia and cancer may be implicated in the pathogenesis and progression of PD. Recent epidemiological studies suggest that some of these comorbidities may increase the risk of PD and precede the onset of motor symptoms. Further, drugs to treat diabetes and cancer have elicited neuroprotective effects in PD models. Nonetheless, the mechanisms underlying the occurrence of these comorbidities remain elusive. Herein, we discuss the biological and clinical implications of comorbidities in the pathogenesis, progression, and clinical management, with an emphasis on personalized medicine applications for PD.

show abstract

Comorbid conditions associated with Parkinson's disease: A longitudinal and comparative study with Alzheimer disease and control subjects

Cited by 36 publications

References 41 publications

COPPADIS‐2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015): an ongoing global Parkinson's disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation

COPPADIS‐2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015): an ongoing global Parkinson's disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation

Multimorbidity and Frailty: Tackling Complexity in Parkinson’s Disease

Biological and Clinical Implications of Comorbidities in Parkinson’s Disease

Contact Info

Product

Resources

About